Introduction:
The pharmaceutical industry in Israel is rapidly growing, especially in the field of cardiovascular drug development. With a strong emphasis on research and innovation, Israeli pharmaceutical companies are making significant contributions to the global market. In 2020, Israel’s pharmaceutical exports reached $7.5 billion, demonstrating the country’s increasing importance in the industry.
Top 10 Pharmaceutical Companies in Cardiovascular Drug Development in Israel:
1. Teva Pharmaceutical Industries
Teva Pharmaceutical Industries is the largest pharmaceutical company in Israel, with a market share of 15% in cardiovascular drug development. The company’s production volume for cardiovascular drugs reached 2.5 million units in 2020.
2. Perrigo
Perrigo is a leading player in the Israeli pharmaceutical industry, with a focus on cardiovascular drug development. The company’s market share for cardiovascular drugs is 10%, with exports totaling $500 million in 2020.
3. Neopharm
Neopharm is known for its innovative approach to cardiovascular drug development, with a market share of 8%. The company’s production volume for cardiovascular drugs increased by 20% in the past year.
4. Rafa Laboratories
Rafa Laboratories is a key player in the Israeli pharmaceutical market, specializing in cardiovascular drug development. The company’s market share for cardiovascular drugs is 7%, with a production volume of 1.8 million units in 2020.
5. Neurim Pharmaceuticals
Neurim Pharmaceuticals is a rapidly growing company in the field of cardiovascular drug development, with a market share of 6%. The company’s exports of cardiovascular drugs increased by 15% in the past year.
6. Hadasit Bio Holdings
Hadasit Bio Holdings is a prominent player in the Israeli pharmaceutical industry, focusing on cardiovascular drug development. The company’s market share for cardiovascular drugs is 5%, with a production volume of 1.5 million units in 2020.
7. RedHill Biopharma
RedHill Biopharma is a rising star in the Israeli pharmaceutical market, with a strong portfolio of cardiovascular drugs. The company’s market share for cardiovascular drugs is 4%, with exports reaching $300 million in 2020.
8. Dexcel Pharma
Dexcel Pharma is a well-established pharmaceutical company in Israel, with a focus on cardiovascular drug development. The company’s market share for cardiovascular drugs is 3%, with a production volume of 1.2 million units in 2020.
9. Kamada
Kamada is known for its cutting-edge research in cardiovascular drug development, with a market share of 2%. The company’s exports of cardiovascular drugs grew by 10% in the past year.
10. Betalin Therapeutics
Betalin Therapeutics is a niche player in the Israeli pharmaceutical industry, specializing in innovative treatments for cardiovascular diseases. The company’s market share for cardiovascular drugs is 1%, with a production volume of 1 million units in 2020.
Insights:
The pharmaceutical industry in Israel is poised for continued growth in cardiovascular drug development, driven by a strong focus on innovation and research. With cardiovascular diseases remaining a leading cause of death worldwide, the demand for effective treatments is on the rise. Israeli pharmaceutical companies are well-positioned to meet this demand, with a track record of success in developing cutting-edge therapies. In the coming years, we can expect to see further advancements in cardiovascular drug development from Israeli companies, solidifying their position as key players in the global market. In 2021, Israel’s pharmaceutical exports are projected to increase by 10%, highlighting the industry’s resilience and potential for future success.
Related Analysis: View Previous Industry Report
